This P30 Cystic Fibrosis (CF) Research and Translational Core Center (CFRTC) will be located at the University of Washington School of Medicine (UWSOM) and its affiliated institution, Seattle Children's Research Institute (SCRI). This proposed P30 center program will enhance an existing robust basic and clinical research base at these institutions totally over $20 million direct costs in external NIH and Cystic Fibrosis Foundation funding ($15 million clinical based, $6 million laboratory based) and including 31 UWSOM investigators in 7 departments and/or divisions. The UWSOM has a long history of excellence in CF related translational research as evidenced by successful development of inhaled tobramycin (TOBI(r)) and leadership in the CFF supported Therapeutics Development Network. The research for this P30 will focus on four emphasis areas: 1) provide resources and expertise to expedite promising new therapeutic approaches to correct absent or dysfunctional CFTR and its secondary consequences, 2) foster sharing of existing and expanding human and bacterial biorepositories to enhance development of new biomarkers and laboratory assays, 3) enhance understanding of bacterial pathogenesis in CF lung disease, and 4) enhance understanding of host inflammatory response and its secondary consequences in CF. The center will be led by co-PI's, Dr. Bonnie Ramsey and Dr. E. Peter Greenberg, CF investigators both nationally recognized in their respective areas of clinical research and bacterial pathogenesis. They will be supported by other core leaders: Dr. William Parks, a senior investigator in modulation of immunity of epithelial mucosa and Dr. Samuel Miller, a senior scientist in bacterial genomics and proteomics. The center will consist of an Administrative Core (Ramsey and Greenberg) and four biomedical cores, Microbiology (Greenberg, Director), Genomics (Miller, Director), Inflammation (Parks, Director) and Clinical Translational (Ramsey, Director). The core centers will operate a Pilot and Feasibility (P&F) program led by Drs. Colin Manoil, a bacterial geneticist, and Ronald Gibson, a CF clinical investigator. Three P&F projects are included in the current proposal chosen through a competitive process from nine applications. During the funding period, the core center will focus on development of several novel therapeutic approaches to improve overall health for patients with CF.

Public Health Relevance

This P30 Research Center will support both basic and clinical studies directed towards advancing new therapies to improve and prolong the lives of patients with Cystic Fibrosis. It will support our large group of researchers at the University of Washington as well as other P30 programs across the US.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK089507-03
Application #
8292198
Study Section
Special Emphasis Panel (ZDK1-GRB-W (M2))
Program Officer
Mckeon, Catherine T
Project Start
2010-07-06
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
3
Fiscal Year
2012
Total Cost
$1,136,517
Indirect Cost
$85,788
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Lundgren, Benjamin R; Villegas-PeƱaranda, Luis Roberto; Harris, Joshua R et al. (2014) Genetic analysis of the assimilation of C5-dicarboxylic acids in Pseudomonas aeruginosa PAO1. J Bacteriol 196:2543-51
Hoffman, Lucas R; Pope, Christopher E; Hayden, Hillary S et al. (2014) Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis. Clin Infect Dis 58:396-9
Mayer-Hamblett, Nicole; Ramsey, Bonnie W; Kulasekara, Hemantha D et al. (2014) Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin Infect Dis 59:624-31
Mayer-Hamblett, Nicole; Rosenfeld, Margaret; Gibson, Ronald L et al. (2014) Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med 190:289-97
Heltshe, Sonya L; Borowitz, Drucy S; Leung, Daniel H et al. (2014) Early attained weight and length predict growth faltering better than velocity measures in infants with CF. J Cyst Fibros 13:723-9
Hewitt, Stephen M; Baskin, Denis G; Frevert, Charles W et al. (2014) Controls for immunohistochemistry: the Histochemical Society's standards of practice for validation of immunohistochemical assays. J Histochem Cytochem 62:693-7
Simard, Marc; Hill, Lesley A; Underhill, Caroline M et al. (2014) Pseudomonas aeruginosa elastase disrupts the cortisol-binding activity of corticosteroid-binding globulin. Endocrinology 155:2900-8
Rowe, Steven M; Heltshe, Sonya L; Gonska, Tanja et al. (2014) Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190:175-84
Cuthbertson, Leah; Rogers, Geraint B; Walker, Alan W et al. (2014) Time between collection and storage significantly influences bacterial sequence composition in sputum samples from cystic fibrosis respiratory infections. J Clin Microbiol 52:3011-6
Majerczyk, Charlotte; Brittnacher, Mitchell; Jacobs, Michael et al. (2014) Global analysis of the Burkholderia thailandensis quorum sensing-controlled regulon. J Bacteriol 196:1412-24

Showing the most recent 10 out of 44 publications